Antithrombotic Monotherapy Efficacy After Left Atrial Appendage Closure
SIMPLAAFY trial compares monotherapy against dual antiplatelet therapy for post-procedure patient outcomes.
1SIMPLAAFY Trial Overview
The SIMPLAAFY trial investigated antithrombotic regimens following left atrial appendage closure in 1,857 patients with nonvalvular atrial fibrillation. Researchers compared aspirin monotherapy, dual antiplatelet therapy, and reduced-dose non-vitamin K oral anticoagulants. The study aimed to determine if simplified medication strategies could effectively manage post-procedure risks while maintaining patient safety.
2Six-Month Clinical Outcomes
At six months, the incidence of combined death, stroke, systemic embolism, or major bleeding was 3.3% for aspirin, 5.1% for reduced-dose NOACs, and 6.9% for DAPT. Statistically, both monotherapy strategies proved at least as effective as the traditional dual antiplatelet therapy approach, suggesting potential for safer, less intensive post-procedural care protocols.
3Device-Related Thrombus Findings
Secondary analyses revealed that low-dose NOAC therapy demonstrated a lower incidence of device-related thrombus at 45 days, recorded at 0.9% compared to 3.4% for DAPT and 2.7% for aspirin. Despite these findings, there was no observed excess in stroke rates across any of the three tested treatment regimens at six months.
4Patient Adherence and Tolerance
Adherence rates for the assigned medications were notably higher in monotherapy groups, with 87.9% for aspirin and 85.3% for reduced-dose NOACs, compared to 76.8% for DAPT. Dr. Saibal Kar noted that both monotherapy treatments were better tolerated by patients, which may contribute to improved long-term management and reduced complications after the procedure.
5Subgroup Analysis Results
A subgroup analysis indicated that patients aged 75 and older experienced disproportionately better outcomes when treated with aspirin or reduced-dose NOACs. These findings suggest that age-specific factors may influence the efficacy of antithrombotic strategies, providing clinicians with data to potentially individualize care based on patient age and specific bleeding risk profiles.
6Contextualizing Clinical Practice
Standard practice for antithrombotic therapy currently varies widely due to a lack of definitive evidence. While the SIMPLAAFY results suggest aspirin may emerge as a strong candidate for post-closure management, experts remain cautious regarding NOACs. Conflicting data from the ANDES trial, which showed higher thrombus rates with NOACs, complicates the clinical picture.
7Study Limitations and Scope
The trial exclusively included patients with uncomplicated Watchman FLX Pro LAA occluder implants, which limits the generalizability of these findings. High-risk populations, including those with severe kidney disease, recent stroke, or myocardial infarction, were excluded from the study. Consequently, these results may not apply to patients with more complex medical histories.
8Future Research Directions
While six-month data supports simplifying antithrombotic management, 12-month results from the SIMPLAAFY trial are still pending. Clinicians remain uncertain about the optimal long-term strategy beyond the one-year mark. Future research is necessary to establish standardized guidelines that balance bleeding risks against the prevention of device-related thrombosis in diverse patient populations.